Vas Narasimhan on the post-pandemic world - Novartis Live. Magazine
Novartis CEO's 2020 pay drops to $11.6M, no thanks to COVID-19's drag on sales | Fierce Pharma
Novartis CEO Vas Narasimhan: How to be a boss in an “unbossed” company - YouTube
Novartis global chief focuses on innovative medicines for Indian market
Cannabinoids are not a focus area" Novartis CEO
Novartis's Vas Narasimhan on AI, Data Science for Company Operations
novartis: Who is Vas Narasimhan? All about the new global chief executive of Swiss pharma giant Novartis - The Economic Times
Vas Narasimhan: the American trying to reshape Novartis | Financial Times
Novartis chief criticises EU move to control pharma licensing in emergencies | Financial Times
Can Novartis Digitally Transform Clinical Development? - TimmermanReport.com
The 'student' of leadership who seeks to inspire his employees | Financial Times
Novartis appointed Vasant Narasimhan as CEO, effective February 1, 2018
Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and more - STAT
Novartis CEO Vas Narasimhan on Culture, Strategy and Change
Novartis CEO Who Wanted To Bring Tech Into Pharma Now Explains Why It's So Hard
Vas Narasimhan | One Young World
Novartis CEO's $50 Billion of Deals Was Just the First Act - Bloomberg
/cloudfront-us-east-2.images.arcpublishing.com/reuters/AQ6AEJN4IJMKPDF4JS6QOCORLM.jpg "Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft | Reuters")
Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft | Reuters
Vas Narasimhan (@VasNarasimhan) / Twitter
Novartis C.E.O. Defends Company's Decision to Withhold False Data From the F.D.A. - The New York Times
CEO's letter - Novartis Novartis in Society Integrated Report 2022
Basel is very open to newcomers - Basel Area Business & Innovation
Vasant Narasimhan - Wikipedia
New Novartis chief eyes productivity revolution - SWI swissinfo.ch
CEO Vas Narasimhan tells employees Novartis' deal with Trump lawyer was a mistake he's determined to overcome | Fierce Pharma
Novartis CEO Says FDA Process Could Have Been Handled Better - Bloomberg
